Uma Borate
A5013231204- Acute Myeloid Leukemia Research
- Chronic Myeloid Leukemia Treatments
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Acute Lymphoblastic Leukemia research
- Histone Deacetylase Inhibitors Research
- Chronic Lymphocytic Leukemia Research
- Protein Degradation and Inhibitors
- Neutropenia and Cancer Infections
- Multiple Myeloma Research and Treatments
- Cancer Genomics and Diagnostics
- Lymphoma Diagnosis and Treatment
- CAR-T cell therapy research
- HIV/AIDS drug development and treatment
- Hematopoietic Stem Cell Transplantation
- Hemoglobinopathies and Related Disorders
- Pneumocystis jirovecii pneumonia detection and treatment
- Cancer-related gene regulation
- Immunodeficiency and Autoimmune Disorders
- Eosinophilic Disorders and Syndromes
- Hematological disorders and diagnostics
- Mast cells and histamine
- Synthetic Organic Chemistry Methods
- Immune cells in cancer
- Advanced biosensing and bioanalysis techniques
- Bone and Joint Diseases
The Ohio State University
2021-2025
The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
2021-2025
Oregon Health & Science University
2016-2024
The Ohio State University Wexner Medical Center
2024
Gilead Sciences (Canada)
2022
GlaxoSmithKline (India)
2022
AstraZeneca (Brazil)
2022
Exact Sciences (United States)
2022
Lantheus Medical Imaging (United States)
2022
Cancer Institute (WIA)
2019
The myelodysplastic syndromes (MDS) represent a heterogeneous group of clonal hematopoietic disorders characterized by cytopenias, dysplasia in one or more myeloid lineages, and the potential for development acute leukemia. These primarily affect older adults. NCCN Clinical Practice Guidelines Oncology MDS provide recommendations on diagnostic evaluation classification MDS, risk according to established prognostic assessment tools (including new revised International Prognostic Scoring...
Glioblastoma (GBM) is the most aggressive nervous system cancer. Understanding its molecular pathogenesis crucial to improving diagnosis and treatment. Integrated analysis of genomic, proteomic, post-translational modification metabolomic data on 99 treatment-naive GBMs provides insights GBM biology. We identify key phosphorylation events (e.g., phosphorylated PTPN11 PLCG1) as potential switches mediating oncogenic pathway activation, well targets for EGFR-, TP53-, RB1-altered tumors. Immune...
We undertook a comprehensive proteogenomic characterization of 95 prospectively collected endometrial carcinomas, comprising 83 endometrioid and 12 serous tumors. This analysis revealed possible new consequences perturbations to the p53 Wnt/β-catenin pathways, identified potential role for circRNAs in epithelial-mesenchymal transition, provided information about proteomic markers clinical genomic tumor subgroups, including relationships known druggable pathways. An extensive genome-wide...
Acute myeloid leukemia (AML) remains the most common form of acute among adults and accounts for largest number annual deaths due to leukemias in United States. The NCCN Clinical Practice Guidelines Oncology (NCCN Guidelines) AML provide recommendations on diagnostic evaluation workup AML, risk assessment based cytogenetic molecular features, treatment options induction consolidation therapies younger older (age ≥ 65 years) adult patients, key supportive care considerations.
We present a proteogenomic study of 108 human papilloma virus (HPV)-negative head and neck squamous cell carcinomas (HNSCCs). Proteomic analysis systematically catalogs HNSCC-associated proteins phosphosites, prioritizes copy number drivers, highlights an oncogenic role for RNA processing genes. investigation mutual exclusivity between FAT1 truncating mutations 11q13.3 amplifications reveals dysregulated actin dynamics as common functional consequence. Phosphoproteomics characterizes two...
Treatment of acute lymphoblastic leukemia (ALL) continues to advance, as evidenced by the improved risk stratification patients and development newer treatment options. Identification ALL subtypes based on immunophenotyping cytogenetic molecular markers has resulted in inclusion Philadelphia-like early T-cell precursor that affect prognosis. Ikaros mutations also emerged a prognostic factor. In addition prognostication, options for with have expanded, particularly regard relapsed/refractory...
Acute myeloid leukemia (AML) is a cancer of myeloid-lineage cells with limited therapeutic options. We previously combined ex vivo drug sensitivity genomic, transcriptomic, and clinical annotations for large cohort AML patients, which facilitated discovery functional genomic correlates. Here, we present dataset that has been harmonized our initial report to yield cumulative 805 patients (942 specimens). show strong cross-cohort concordance identify features response. Further, deconvoluting...
The NCCN Guidelines for Myelodysplastic Syndromes (MDS) provide recommendations the evaluation, diagnosis, and management of patients with MDS based on a review clinical evidence that has led to important advances in treatment or yielded new information biologic factors may have prognostic significance MDS. multidisciplinary panel experts meets an annual basis update recommendations. These Insights focus some updates 2022 version Guidelines, which include both lower-risk higher-risk MDS,...
These NCCN Guidelines Insights summarize several key updates to the for Acute Myeloid Leukemia and discuss clinical evidence that support recommendations. The described in this article focus on acute promyelocytic leukemia (APL) section, featuring recommendations additional induction/consolidation regimens patients with low- or intermediate-risk APL, providing guidance maintenance strategies APL.
Key Points Addition of dasatinib to chemotherapy followed by allogeneic stem cell transplant is well tolerated in younger patients with Ph+ ALL. Landmark analysis showed statistically superior advantages for relapse-free and overall survival the transplanted patients.
Patients with relapsed/refractory (R/R) higher-risk myelodysplastic syndromes (MDS) have a dismal median overall survival (OS) after failing hypomethylating agent (HMA) treatment. There is no standard of care for patients HMA therapy failure; hence, there critical need effective therapeutic strategies. Herein, we present the safety and efficacy venetoclax + azacitidine in R/R MDS. This phase 1b, open-label, multicenter study enrolled ≥18 years. were treated escalating doses oral venetoclax:...
Abstract Ruxolitinib reduces spleen volume, improves symptoms, and increases survival in patients with intermediate- or high-risk myelofibrosis. However, suboptimal response may occur, potentially because of signaling via the phosphoinositide 3-kinase (PI3K)/protein kinase B pathway. This phase 2 study evaluated dosing, efficacy, safety add-on PI3Kδ inhibitor parsaclisib for primary secondary myelofibrosis to ruxolitinib. Eligible remained on a stable ruxolitinib dose received 10 20 mg, once...
Progress has been made in determining the biological variants of acute myelogenous leukemia (AML) and their prognostic implications. However, to authors' knowledge, little is known regarding impact nonbiological factors (NBFs) on survival patients with AML.The NBFs (marital status, insurance county-level income, education) was assessed along (disease subtype, sex, age, race/ethnicity) using a cohort aged 19 64 years who were diagnosed AML between 2007 2011 reported Surveillance,...